TCGA-CV-6954-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.457077626
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.430
- PANCREAS_BETA_CELLS+0.340
- OXIDATIVE_PHOSPHORYLATION+0.330
- INTERFERON_GAMMA_RESPONSE+0.310
- PROTEIN_SECRETION+0.300
- MYC_TARGETS_V2+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.180
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.140
- MYC_TARGETS_V1+0.120
- ANGIOGENESIS+0.100
Top 10 suppressed
- APICAL_SURFACE-0.380
- HEDGEHOG_SIGNALING-0.350
- IL2_STAT5_SIGNALING-0.280
- E2F_TARGETS-0.210
- MYOGENESIS-0.210
- APICAL_JUNCTION-0.190
- G2M_CHECKPOINT-0.170
- MITOTIC_SPINDLE-0.170
- IL6_JAK_STAT3_SIGNALING-0.160
- ESTROGEN_RESPONSE_EARLY-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X7c156f05.aaca.4c79.bdb2.94044d5422e8 | — | cohortA1 | 0.723 |
| 2 | TCGA-QK-A64Z-01A-11R-A30B-07 | — | — | 0.608 |
| 3 | R324 | — | — | 0.579 |
| 4 | SRR23303762 | — | — | 0.568 |
| 5 | DRR168578 | — | — | 0.561 |
| 6 | C3N-01023 | — | cohortA3 | 0.557 |
| 7 | TCGA-OR-A5LM-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.554 |
| 8 | C3N-01415 | — | cohortA1 | 0.551 |
| 9 | TCGA-75-5147-01A-01R-1628-07 | — | cohortA1 | 0.548 |
| 10 | MNG85 | — | — | 0.542 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.040 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |